Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
Deutsche Version Deutsche Version
  MedUni Vienna    Intranet    MedUni Vienna - Shop    University Library    University Hospital Vienna  
 
Krebsforschung_EN.png
 
 
 
Hauptnavigation
  • Home
  • General Information
    • History
    • 50 years Institute for Cancer Research
    • Imagevideo: Institute for Cancer Research
  • Research
    • Research Focus
    • Research Laboratories
    • Scientific Services - Core Facilities
  • Teaching
    • Lectures of the Institute of Cancer Research
    • University Course Toxicology for Postgraduates
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Program Malignant Diseases
    • PhD Program Clinical and Experimental Oncology
  • Contact
    • Contact
    • Map
 
Research / Research Focus / Cellular and Molecular Tumorbiology / Thomas Vogl
 
Subnavigation
  • Research Focus
    • Cellular and Molecular Tumorbiology
      • Maria Sibilia
      • Thomas Bauer
      • Robert Eferl
      • Andrea Gsur
      • Erich Heidenreich
      • Dietmar Herndler-Brandstetter
      • Kazuhiko Matsuoka
      • Ferdinand Steinböck
      • Thomas Vogl
        • Research Projects
    • Applied and Experimental Oncology
    • Chemical Safety and Cancer Prevention
    • Tumor Progression and Metastasis
  • Research Laboratories
  • Scientific Services - Core Facilities


Inhaltsbereich

Thomas Vogl, Dr. rer.nat. BSc. MSc.
Group Leader
Phone: +43-1-40160-57529
E-Mail: thomas.vogl [at] meduniwien [dot] ac [dot] at

 

 

 

Research Focus

The interplay between the immune system and microbes in cancer

In principle, our immune system is capable of detecting cancer cells, preventing tumors from growing, and even destroying them. However, cancer cells may evade the body's own defenses through new mutations. How well patients respond to certain cancer therapies therefore depends on many factors, such as their immune system and molecular properties of the tumor.

However, rather unexpected aspects of human health also influence the response to certain cancer therapies: In recent years it has been shown that immunotherapies are beneficially affected by a diverse, healthy composition of intestinal microbes. The gut microbiome refers to the collective of bacteria living in our intestines. These strains can play a significant role in activating the immune system in responding appropriately to cancer cells. The composition of the microbiome in the digestive tract, which contains by far the largest number of bacteria on the human body, can significantly influence the success of certain therapies. At the same time, however, other bacterial strains have been linked to the occurrence of certain cancers, such as colorectal cancer. How the immune system differentiates between beneficial and harmful microbes, and how these individually influence cancers, is only incompletely understood.

Dr. Thomas Vogl and his multidisciplinary team of molecular biologists, biochemists, and bioinformaticians are investigating which microbial and tumor factors are crucial for successful cancer therapies. Dr. Vogl's expertise lies in the combination of biological experiments with computer-assisted analyses. In this context, the immune system is analyzed in the laboratory using blood samples from patients alongside novel high-throughput methods.

The main focus lies on the investigation of antibody responses against the microbiome. A better understanding of the complex interaction between the intestinal microbes and our immune system could improve the prevention of cancer and pave the way towards novel therapies.

 

 

Selected Publications

Population-wide diversity and stability of serum antibody epitope repertoires against human microbiota
Vogl T., Klompus K., Leviatan S. Kalka I.N., Weinberger A., Wijmenga C., Fu J., Zhernakova A., Weersma R.K., Segal E.
Nat Med. 2021 Aug;27(8):1442-1450. doi: 10.1038/s41591-021-01409-3.

Systemic antibody responses against human microbiota flagellins are overrepresented in chronic fatigue syndrome (ME/CFS) patients
Vogl T.#, Kalka I.N., Klompus S., Leviatan S., Weinberger A., Segal E.#.
# Corresponding author
Sci Adv 2022 Sep 23;8(38):eabq2422. doi: 10.1126/sciadv.abq2422. Epub 2022 Sep 23.

Allergenic food protein consumption is associated with systemic IgG antibody responses in non-allergic individuals
Leviatan S.*, Vogl T.*#, Klompus S.*, Kalka I.N.*, Weinberger A., Segal E.#.
# Corresponding author
Immunity. 2022 Dec 13;55(12):2454-2469.e6. doi: 10.1016/j.immuni.2022.11.004. Epub 2022 Dec 5.

Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers
Klompus S.*, Leviatan S.*, Vogl T.#*., Mazor R.D.*, Kalka I.N., Stoler-Barak L., Nathan N., Peres A., Moss L., Godneva A., Sharon Kagan Ben Tikva, Shinar E., Cohen Dvashi H., Gabizon R., London N., Diskin R., Yaari G., Weinberger A., Shulman Z.#, Segal E.#
# Corresponding author
Sci Immunol. 2021 Jul 29;6(61):eabe9950. doi: 10.1126/sciimmunol.abe9950.

SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
Vogl T.#, Leviatan S., Segal E.#.
# Corresponding author
Cell Rep Med. 2021 Feb 16;2(2):100191. doi: 10.1016/j.xcrm.2021.100191.

Engineered bidirectional promoters enable rapid multi-gene co-expression optimization
Vogl T., Kickenweiz T., Pitzer J., Sturmberger L., Weninger A., Biggs BW., Köhler E-M., Baumschlager A., Fischer JE., Hyden P., Wagner M., Baumann M., Borth N., Geier M., Ajikumar PK., Glieder A.
Nat Commun. 2018 Sep 4;9(1):3589. doi: 10.1038/s41467-018-05915-w.

All Publications

Google scholar profile

 
Print
 
 
© MedUni Wien | Publishing information | Terms of use | Data Protection | Accessibility | Contact